QIAGEN Expands Tuberculosis Portfolio With New NGS Panel To Support Real-Time Surveillance And Combat Antimicrobial Resistance
QIAGEN Expands Tuberculosis Portfolio With New NGS Panel To Support Real-Time Surveillance And Combat Antimicrobial Resistance
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB), the world's leading infectious disease killer.
QIAGEN（纽约证券交易所代码：QGEN，法兰克福主要标准：QIA））））今天宣布推出供研究使用的QiaseQ xHYB结核分枝杆菌试剂盒，这是对抗结核病（TB）的新工具，结核病是世界领先的传染病杀手。
Building on QIAGEN's ongoing efforts to support global TB management and control, which include the leading diagnostics test QuantiFERON-TB Gold Plus, the new panel enables culture-free whole genome sequencing (WGS) directly from samples such as sputum or cerebrospinal fluid. This innovation significantly reduces the time to result and enables real-time epidemiology of TB outbreaks, addressing a critical need in the field of TB surveillance and control.
在QIAGEN持续努力支持全球结核病管理和控制（包括领先的诊断测试Quantiferon-TB Gold Plus）的基础上，新试剂盒支持直接从痰液或脑脊液等样本中进行无培养全基因组测序（WGS）。这项创新显著缩短了得出结果的时间，实现了结核病疫情的实时流行病学，满足了结核病监测和控制领域的关键需求。
The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS). It is designed against the seven major lineages of TB, covering the full breadth of diversity. By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
QiaseQ xHYB 结核分枝杆菌试剂盒代表了在使用下一代测序 (NGS) 从复杂宿主样本中解决细菌 WGS 问题方面取得的重大进展。它针对结核病的七个主要谱系而设计，涵盖了所有多样性。通过无需进行4至6周的细菌培养，该小组显著加快了获得结果的过程。
"The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance," said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN. "This innovative panel not only streamlines the workflow for healthcare professionals and researchers but also enables the real-time tracking of TB outbreaks, a crucial aspect in combating the spread of this devastating disease and managing the growing threat of drug-resistant TB."
QIAGEN副总裁兼生命科学业务领域负责人Nitin Sood表示：“QiaseQ xHYB结核分枝杆菌小组的推出反映了我们对应对结核病和抗微生物药物耐药性等全球健康挑战的持续承诺。“这个创新的面板不仅简化了医疗保健专业人员和研究人员的工作流程，而且可以实时跟踪结核病疫情，这是抗击这种毁灭性疾病传播和管理日益增长的耐药结核病威胁的关键方面。”
"Innovative aspects of this workflow are the whole genome analysis from clinical samples, avoidance of the culturing delay, and inclusion of genetic diversity," stated Daniela Maria Cirillo, MD, PhD, Head of Emerging Bacterial Pathogens Unit at IRCCS San Raffaele Scientific Institute, Milan, Italy.
意大利米兰IRCCS圣拉斐尔科学研究所新兴细菌病原体部门负责人丹妮拉·玛丽亚·西里洛医学博士说：“该工作流程的创新方面是对临床样本进行全基因组分析，避免培养延迟，以及纳入遗传多样性。”
The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment. The panel covers all AMR-related genes, allowing for the identification of resistant TB strains, including multidrug-resistant tuberculosis (MDR-TB), which is caused by bacteria that do not respond to the most effective first-line TB drugs.
QiaseQ xHYB结核分枝杆菌小组在抗微生物药物耐药性（AMR）的检测和管理中也发挥着至关重要的作用，抗微生物药物耐药性（AMR）是结核病治疗中日益受到关注的问题。该小组涵盖了所有抗微生物耐药性相关基因，从而可以鉴定出耐药结核菌株，包括耐多药结核（MDR-TB），耐多药结核病是由对最有效的一线结核药物无反应的细菌引起的。